CD274 and liposarcoma: The use of anti PD-L1 mAb—such as avelumab, atezolizumab and durvalumab—has also been evaluated both with, or without, combined therapy in clinical trials on STS such as liposarcomas, leiomyosarcomas, Synovial sarcoma, angiosarcoma and Ewing sarcoma (NCT030074318, NCT02609984, NCT03111729, NCT030176529, NCT03111729, NCT0301765 in clinicaltrials.gov/, accessed on 31 May 2021).